243
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Renoprotective Effect of Calcium Channel Blockers in Combination with an Angiotensin Receptor Blocker in Elderly Patients with Hypertension. A Randomized Crossover Trial Between Benidipine and Amlodipine

, , , , , & show all
Pages 1-7 | Received 30 Jun 2008, Accepted 18 Aug 2008, Published online: 10 Feb 2010
 

Abstract

Anti-hypertensive medication with an angiotensin II receptor blocker (ARB) is effective in slowing the progression of chronic kidney disease. The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function. Elderly hypertensive patients with chronic kidney disease (n = 17, 72 ± 6 years old) were instructed to self-measure blood pressure. They were randomly assigned to receive either benidipine (4–8 mg/day) or amlodipine (5–10 mg/day) combined with olmesartan (10 mg/day). After 3 months, CCBs were switched in each patient and the same protocol was applied for another 3 months. At baseline, significant correlation was obtained between urine albumin (22.8 ± 16.7 (median ± median absolute deviation) mg/g creatinine) and self-measured blood pressure (170 ± 23/87 ± 10 (mean ± SD) mmHg, r = 0.65, p < 0.01). Both regimens reduced blood pressure to a similar extent (139 ± 22/75 ± 11 mmHg and 133 ± 17/72 ± 10 mmHg, respectively; both p < 0.001), while urine albumin decreased only after combination therapy including benidipine (11.7 ± 6.1 mg/g creatinine, p < 0.05). Benidipine, but not amlodipine, in combination with olmesartan, reduced urinary albumin excretion in elderly hypertensive patients with chronic kidney disease. The results suggest the importance of selecting medications used in combination with ARB in hypertensive patients with chronic kidney disease.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.